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           TGF-β plays an important role in differentiation and tissue morphogenesis as well as 
cancer progression. However, the role of TGF-β in cancer is complicate. TGF-β has 
primarily been recognized as tumor suppressor, because it can directly inhibit cell 
proliferation of normal and premalignant epithelial cell. However, in the last stage of tumor 
progression, TGF-β functions as tumor promoter to enhance tumor cells metastatic 
dissemination and expands metastatic colonies. Currently, the mechanism of how TGF-β 
switches its role from tumor suppressor to promoter still remains elusive. Here we identify 
that overexpression of 14-3-3ζ inhibits TGF-β’s cell cytostatic program through 
destabilizing p53 in non-transformed human mammary epithelial cells. Mechanistically, we 
found that 14-3-3ζ overexpression leads to 14-3-3σ downregulation, thereby activates 
PI3K/Akt signaling pathway and degrades p53, and further inhibits TGF-β induced p21 
expression and cell cytostatic function. In addition, we found that overexpression of 14-3-
3ζ promotes TGF-β induced breast cancer cells bone metastatic colonization through 
stabilizing Gli2, which is an important co-transcriptional factor for p-smad2 to activate 
PTHrP expression and bone osteolytic effect. Taken together, we reveal a novel mechanism 
that 14-3-3ζ dictates the tumor suppressor or metastases promoter activities of TGF-β 
 vii
signaling pathway through switching p-smad2 binding partner from p53 to Gli2. The 
expected results will not only provide us the better understanding of the important role of 
14-3-3ζ in the early stage of breast cancer development, but also deeply impact our 
knowledge of signaling mechanisms underlying the complex roles of TGF-β in cancer, 
which will give us a more accurate strategy to determine when and how anti-TGF-β 
targeted therapy might be effective. 
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Chapter 1: Introduction 
Breast cancer development and progression 
         The development of breast cancer is a multistep process. Based on epidemiological 
and histological observations, these steps are defined as a series of morphological and 
cytological changes from normal epithelium, to ductal hyperplasia, to atypical ductal 
hyperplasia (ADH), to ductal carcinoma in situ (DCIS), and finally to invasive carcinoma. 
During this transformation process, there are a multitude of genetic and epigenetic changes 
accumulated. Currently, the molecular mechanisms underlying this process are still elusive 
(1, 2). Previously, we discovered that an increase in the expression of 14-3-3ζ begins at 
ADH, an early stage of breast cancer development, suggesting that 14-3-3ζ overexpression 
may play an important role in breast cancer initiation (3).  
TGF-β’s dual role in cancer development 
         TGF-β plays an important role in differentiation and tissue morphogenesis as well as 
cancer progression. It has been well characterized that TGF-β binds to its receptor on the 
cell membrane and induces a signaling cascade by phosphorylating smad2/3. 
Phosphorylated smad2/3 binds to smad4 and the complex translocates from the cytoplasm to 
the nucleus to activate the transcription of end effectors, like p15, p21, PTHrP, and others 
(4, 5). However, the role of TGF-β in cancer is complicated. TGF-β has primarily been 
recognized as a tumor suppressor because it can directly inhibit cell proliferation or induce 
apoptosis of normal and premalignant epithelial cells (6). However, in late stage of tumor 
progression, TGF-β functions as a tumor promoter because it induces an Epithelial-
Mesenchymal transition (EMT) increasing the ability of malignant cells to evade immune 
surveillance and establish metastatic colonies in the second organ sites, (e.g. lung, bone, 
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liver, and brain) (6). How TGF-β switches its role from a tumor suppressor to promoter 
remains unsolved in the field. In addition, the importance of TGF-β signaling pathways in 
cancer has spurred the development of anti-TGFβ compounds that therapeutically target 
TGF-β and yet fail to show clinical efficacy (7-9). A new paradigm is unraveling in the field 
of personalized medicine that has shed light on the need to develop biomarkers with which 
to identify the stage women will most likely show a response to anti-TGFβ compounds, and 
how to conduct trials using biomarker-guided patient selection and efficacy evaluation. 
14-3-3 family members in cancer 
         The 14-3-3 proteins constitute a family of evolutionarily conserved and ubiquitously 
expressed proteins in eukaryotic organisms, with seven isoforms in mammals cells denoted 
as β, γ, ε, η, σ, τ, and ζ (10). These 29-31 kDa acidic proteins bind to specific motifs on 
target proteins in a phosphorylation-dependent manner (11-14). 14-3-3 proteins function 
through forming hetero- or homo-dimers to physically interact with specific client proteins 
and thereby lead to an alteration in these proteins (i.e. sequestration, prevention of 
degradation, and alteration of enzymatic activity). As a result, 14-3-3 proteins are involved 
in many cellular processes such as cell-cell adhesion, cell-cycle control, apoptosis, and cell 
metabolism (11, 13, 15). In fact, the different isoforms have distinct roles in cells. 14-3-3σ is 
well recognized as a tumor suppressor as a G2/M gatekeeper (16). Conversely, 14-3-3ζ has 
been identified as an oncogenic isoform and overexpression of 14-3-3ζ is associated with 
multiple cancer types and regulates various pathways that promote cancer initiation and 
progression (3). For example, 14-3-3ζ overexpression leads to activation of PI3K-Akt 
signaling pathway thereby downregulating the tumor suppressor p53 (3, 17). In addition, we 
have reported that 14-3-3ζ is overexpressed in >40% of advanced stage breast cancers and 
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has a strong correlation with disease recurrence and poor survival in breast cancer patients 
(18). In addition, we have found that 14-3-3ζ overexpression can promote breast cancer 
progression from early stage (DCIS) to late stage (IDC) via Epithelial-Mesenchymal 
Transition (EMT) through binding and stabilizing TGFβR1 and activating TGF-β pathway 
(19). These lines of evidence strongly suggest that deregulation of 14-3-3 proteins may play 
an important role in cancer initiation and progression and may be a potential target for 
developing anticancer therapeutics. 
Genetic and epigenetic regulation of 14-3-3 σ  
        Among the 14-3-3 family, 14-3-3 σ, also known as human epithelial marker (HEM) or 
stratifin, is well recognized as a tumor suppressor gene, and is lost in multiple types of 
cancer. The expression of 14-3-3σ can be regulated by different mechanisms. 14-3-3σ is 
regulated by another tumor suppressor gene, p53, which is strongly induced by ionizing 
radiation and DNA damage. p53 is dephosphorylated and activated following cellular DNA 
damage, and it then binds to the promoter region of 14-3-3σ, and leads to increased 
transcription of 14-3-3σ and G2/M arrest (16, 20). 14-3-3σ expression in basal/progenitor 
cell may be repressed by ΔNp63, a dominant negative isoform which can suppress both p53 
and TAp63 transactivation (21-23). Moreover, 14-3-3σ can be regulated by estrogen-
induced zinc finger protein (EFP). In breast epithelial cells, EFP acts as an E3 ligase to 
ubiquitinate 14-3-3σ that is then quickly degraded (24).  
        Gene silencing of 14-3-3σ, mainly modulated by CpG methylation in the promoter 
region, occurs in several types of solid tumor, including prostate, lung, breast, skin cancer, 
and also in hematologic malignancies (25-31). Epigenetic inactivation of 14-3-3σ is a very 
early event in carcinogensis and the extent of 14-3-3σ promoter hypermethylation gradually 
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increases from the early stage to late stage during the breast cancer progression, (i.e. atypical 
hyperplasia (38%), ductal carcinoma in situ (83%), and invasive ductal carcinoma (96%)) 
(28). Although p53 and ΔNp63 have been reported to be the major regulator of 14-3-3σ 
expression in cell lines, no association between 14-3-3σ expression and p53 mutations or 
increased level of ΔNp63 was seen in human tissue, suggesting that the constitutive 
expression of 14-3-3σ may be dependent on factors other than p53 (32, 33). Recently, IKKα 
was found to be an important transcription factor of 14-3-3σ, as it can directly prevent 
Histone H3-K9 trimethylase Suv39h1 and Dnmt3a access to 14-3-3σ promoter, thereby 
preventing hypermethylation of 14-3-3σ (34).  
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Chapter 2: Methods and Materials 
Cell line and cell culture:  
        MCF-10A cell line was a kind gift from Dr. Robert Pauley (Karmonos Cancer Institute, 
Detroit, MI), and was cultured in MCF-10A medium : Dulbecco’s Modified Eagle’s 
Medium (DMEM, Caisson Labs) supplemented with 5% Horse Serum (Invitrogen, CA), 
20ng/ml epidermal growth factor (EGF), 10 μg/ml insulin, 0.5 μg/ml hydrocortisone 
(Sigma-Aldrich, MO), 100 ng/ml cholera toxin (Calbiochem, Darmstadt, Germany). MCF-
12A, MDA-MB-231 cell lines were obtained from American Type Culture Collection 
(ATCC). MCF-10A and MCF-12A cell lines and their genetically modified variants were 
maintained in MCF-10A medium. MDA-MB-231 cell line and its genetically modified 
variants was maintained in DMEM with 10% FBS and antibiotics. The murine osteoblast 
cell line MC3T3 was a kind gift from Dr. Sue-Hwa Lin (Department of Molecular 
Pathology, M.D. Anderson Cancer Center), and was maintained in growth medium αMEM 
supplemented with 10% FBS and antibiotics. The murine pre-osteoclast cell line RAW 
264.7 was a kind gift from Dr. Bharat B. Aggarwal (Department of Experimental 
Therapeutics, M.D. Anderson Cancer Center), and was maintained in DMEM with 10% 
FBS and antibiotics for regular culture and supplemented with 30ng/ml RANKL for 
osteoclastogenesis assays. 
Antibodies and Reagents:  
         Antibodies for 14-3-3ζ (sc-1019), p53 (sc-126) , smad4 (sc-7966), Lamin B (sc-6217) 
were purchased from Santa Cruz Biotech; 14-3-3σ (ab14123), Gli2 (ab7195) antibodies 
were purchased from Abcam; Foxo3a (07-102) antibody was purchased from Millipore; p21 
(610234) antibody was purchased from BD Transduction Laboratories; β-actin (A2172) and 
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tubulin (T6199) antibodies were purchased from Sigma-Aldrich; p-Akt (4058), T-Akt 
(9272), T-smad2/3(3102), p-YAP1 (4911), T-YAP1 (4912), smad2 (3122), smad3 (9513), p-
smad2 (3101) and p-smad3 (9520) antibodies were purchased from Cell Signaling 
Technology; antibody for p53(OP03, Calbiochem) and smad2 were used for 
immunoprecipitation assay as previously described(35). Recombinant Human TGFβ1(4342-
5) was purchased from BioVison, and diluted in 1xPBS at 5ng/ml concentration; TGF-β 
Receptor 1 kinase inhibitor (LY2109761, Eli Lily) was kindly provided by Eli Lily through 
collaboration.  
Western blot analysis:  
          Total cell lysates were collected with immunoprecipitation (IP) lysis Buffer (20 mM 
Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM beta-glycerolphosphate, 1 mM sodium orthovanadate,1 mM 
PMSF and protease inhibitor cocktail). Whole cell lysates were obtained by sonication 
followed by centrifugation. Protein concentration was measured by BCA protein assay kit 
(Pierce). Equal amounts of cell lysates were subjected to electrophoresis using SDS-PAGE 
and transferred to Polyvinyldifluoride membrane (Bio-Rad). Membranes were blocked with 
5% milk (in PBS-T) for 30 min, followed by primary antibody incubation overnight at 4oC, 
and after three washes with PBST (5 min each), incubated with secondary antibody (5%milk 
in PBS-T ) for 60 min, and signal was detected by ECL (Amersham) following the 
manufacturer’s instructions. 
Cell proliferation assay, BrdU incorporation assay: 
         Cells were plated at 1 x 104 cells/plate in triplicate in 10 cm cell culture plates for both 
control and TGF-β treatment (5ng/ml). At each time point (24, 48 and 72 hrs), cells were 
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trypsinized and live cells were counted using hemocytometer. BrdU incorporation assay was 
performed following instruction of BrdU Cell Proliferation Kit (Millipore) after treatment 
with TGF-β (5ng/ml) or vehicle. The percentage of cell proliferation was calculated after 72 
hours treatment and normalized to the group without treatment. 
Immunoprecipitation:  
         Cell lysates were prepared as previously described. Cell lysates (1000μg) were diluted 
with IP buffer, and then pre-cleared by incubation with 2μg of isotype matched IgG and 35 
μl protein G-linked agarose beads (Roche Diagnostic) for 2 hour at 4oC. After pre-clearing 
lysates were incubated with 1 μg specific antibody overnight at 4oC, followed by incubation 
with 50μl protein-G linked agarose beads for 1 hour. The beads were then pelleted at 1000 
rpm and washed with cold IP buffer for three X 10 min. The washed immunoprecipitated 
complex was mixed with 2X loading buffer (100 mM Tris-HCL [pH 6.8], 200 mM DTT, 
4% SDS, 0.2% Bromophenol blue, 20% glycerol) at a 1:1 ratio and denatured by boiling for 
5 min, followed by western blot analysis with specific antibodies as described previously. 
Luciferase reporter assay:  
          Genomic DNA was extracted from MCF-10A parental cells (Purelink Genomic DNA 
mini kit, invitrogen) and used as template to clone the 14-3-3σ promoter fragment with the 
following primers: 741 forward 5’-GGCCTGGAGGATGGAACC-3’; 922 forward 5’-
CAACTTGAAAGGGAAATTGTGTAG-3’; 1221 forward 5’-
CATCACGTAGCTGGAATTGCTG-3’; shared reverse 5’-TCTCCTCCGAGCCCTCCT-3’ 
as indicated in Figure 16. The PCR product was then cloned into pGL3 luciferase vector to 
generate sequential deletion mutations of pGL3.14-3-3σ luciferase reporter. For specific 
transcription factor binding site mutations in 181 bp promoter region, the following primers 
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for M1: F1: 5’-AAGGGAAAATTGTGTAGTAAAAAAAAATGTG-3’, R1: 5’-
GGTTTGTTGGACACATTTTTTTTTACTACAC-3’; M2: F2: 5’- 
CCAACAAACCTACTGGGTAAAAAAAAAAAAAGGCTGG-3’, R2: 5’- 
GCTCCAGCCCAGCCTTTTTTTTTTTTTACCCAGTA-3’; M3: F3: 5’-
GCACTCTGAAAGCTGCCAAAAAAACATTCTGG-3’, R3: 5’- 
CCCTCTGAGCTCCCAGAATGTTTTTTTGGCAGC-3’; M4: F4: 5’-
GCTCAGAGGGGACCCTGAAAAAAAATGAGG-3’, R4: 5’- 
CCATCCTCCAGGCCTCATTTTTTTTCAGGGTCCC-3’; M5: F5: 5’-
GCGCATTCTGGGAGCTCAAAAAAAACCCTGAG-3’, R5: 5’- 
CCTCATTCCCCCTCAGGGTTTTTTTTGAGCTCC-3’; were used to generate the mutated 
clones. Luciferase reporter plasmids were co-transfected into target cells with Renilla-Tk 
luciferase vectors (Promega) as transfection efficiency control by Amaxa Nucleofector 
transfection with program T-24. After 48 hours, the reporter luciferase activity was 
measured and normalized to control Renilla luciferase activity by Dual-Luciferase Reporter 
Assay system from Promega following the manufacturer’s instructions.  
mRNA stability assay: 
        Equal numbers of cells were plated in 10-cm plates and incubated at 37°C until they 
reached 70% confluence. Cells were treated with 5 μg/ml antinomycin D for 0, 1, 2, or 4 
hours. Total RNA was extracted with TRIzol reagent (Invitrogen, San Diego, CA), and qRT-
PCR analysis was performed to determine the relative mRNA level of 14-3-3σ. 
Bisulfite genomic sequencing: 
       Dilute 1-2 μg genomic DNA extracted from MCF-10A.vec or MCF-10A.14-3-3ζ cells 
into 50μl distilled H2O.  Add 5.5μl of 2M NaOH and incubate at 37°C for 10 minutes to 
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create single stranded DNA. At the same time, freshly prepare 10mM hydroquinone (sigma) 
buffer (55 mg hydrochinone in 50 ml of water) and add 30μl into DNA. Add 520μl freshly 
prepared 3M sodium bisulfite(sigma s-8890) solutions: mix 1.88g of sodium bisulfite with 5 
ml of water and adjusting pH to 5.0 with NaOH. Incubate DNA mixture at 50°C for 16 
hours. Use DNA wizard cleanup kit (Promega A7280) to recover DNA, and Resuspend in 
50μl TE buffer, and mix well. Desulfonate the DNA by adding 5.5μl of 3M NaOH and 
incubating at room temperature for 5 mins. Precipitate DNA by adding 1μl glycogen 
(Boehringer) as carrier, 33μl of 10M NH4Ac, and 3 volumes of ethanol. Incubate overnight 
at -20°C, then mix and centrifuge DNA for 30 mins at 4°C. Wash pellet in 70% ethanol and 
then air dry (as described above) and resuspend in 50μl TE buffer. At this stage the sample 
can be kept in the refrigerator over night.  
          Methylation status was analyzed by bisulfite genomic sequencing of both strands of 
the corresponding CpG islands. Ten independent clones for each sample were analyzed. The 
bisulfite-modified DNA was then amplified by methylation-specific PCR using primer pairs 
that specifically amplify two regions of 14-3-3σ promoter. A 580bp sequence containing 7 
CpG dinucleotides (Figure 1A) was amplified using Sigma-MR1 (5'-
AACAACACCCTCCAAACAACC-3') and Sigma-MF1(5'-
GGAAGGGTATTGTGAAAGTGGA-3'); A 770bp sequence containing 20 CpG 
dinucleotides was amplified using Sigma-MR2 (5'-AAAACCTCCCACCCCATACT-3')  
and Sigma-MF2 (5’-TGAGGATATGGTAGTTTTTATGAAAGG-3’). Cycling conditions 
were: 95°C/5 min × 1 cycle; 95°C/45 sec, 59°C/30 sec, 72°C/30 sec × 31 cycles; 72°C/5 min 
× 1 cycle. Gel extracted PCR products were subcloned into pCR2.1-Topo vector (Topo TA 
cloning kit, Invitrogen, Carlsbad, CA) and transformed into competent DH5α Escherichia 
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coli cells (Invitrogen). Plasmid DNA was purified with Qiagen Maxi or Midi kits (Qiagen, 
Valencia, CA) and sequenced using universal T3 and/or T7 primers. Sequencing was 
performed by the MDACC core facility.  
5-Aza-2′-deoxycytidine treatment: 
         MCF-10A sublines were treated with 0, 2.5, or 5 μM of the hypomethylating reagent 
5-aza-2-deoxycytidine (DAC; Sigma, St. Louis, MO) respectively. Fresh DAC was added 
daily for 5 days, after which cell lysates were collected for western blot analysis.  
Protein stability assay:  
         MG-132 (10 μM; Calbiochem) was given to the target cells to inhibit proteasome-
mediated protein degradation as previously described (3). Cell lysates are collected at the 
time points of 4, 8, or 16 hours and western blot analysis of p53, p21, 14-3-3σ and 14-3-3ζ 
protein level. β-actin was used as a loading control.  
Generation of knockdown and overexpression cells: 
           Stable shRNA-mediated knockdown was achieved with the pLKO.1-puro system 
(MISSION RNAi, Sigma-Aldrich) targeting two coding sequence: shRNA535 
(CCGGGACAGATTTCTACCACTCCAACTCGAGTTGGAGTGGTAGAAATCTGTCTT
TTTG); and shRNA233 
(CCGGGAGCGATGGAACTTCGACTTTCTCGAGAAAGTCGAAGTTCCATCGCTCTT
TTTG) for p21. shRNA lentiviral vectors were transfected into the packaging cell line 293T 
together with two other plasmids: packaging DNA (psPAX2) and envelope DNA (pMD2G) 
through Lipofectamine transfection. After 48 hours viruses were collected, filtered and used 
to infect target cells in the presence of 8-10μg/ml polybrene for 24 hours. The infected 
MCF-10A cells were selected with 2μg/ml puromycin. To stably knockdown 14-3-3σ, two 
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14-3-3σ shRNA lentiviral plasmids (RefSeq NM_006142, Sigma-Aldrich) targeting 14-3-3σ 
3’-UTR and coding sequence were used in the experiments:  shRNA128 
(CCGGCTGCCTCTGATCGTAGGAATTCTCGAGAATTCCTACGATCAGAGGCAGTT
TTTG); and shRNA130 
(CCGGGACGACAAGAAGCGCATCATTCTCGAGAATGATGCGCTTCTTGTCGTCTT
TTTG). For stable knockdown of 14-3-3ζ in the MDA231 breast cancer cell line, three 
shRNA clone (RefSeq NM_003406) were purchased from Sigma-Aldrich targeting the 
coding sequence: shRNA4 
(CCGGGCAGAGAGCAAAGTCTTCTATCTCGAGATAGAAGACTTTGCTCTCTGCTT
TTT); shRNA5 
(CCGGGCAATTACTGAGAGACAACTTCTCGAGAAGTTGTCTCTCAGTAATTGCTT
TTT); and shRNA8 
(CCGGCTCTGTGTTCTATTATGAGATCTCGAGATCTCATAATAGAACACAGAGTT
TTT). Viruses were generated and used to infect target cells as above and then subsequently 
selected with 3μg/ml puromycin in MDA231 cells. Control cell lines were derived from 
parental vector alone.  
           For stable knockdown of YAP1, three Lentiviral shRNAs targeting the YAP-1 coding 
sequence were purchased from Open Biosystems: shRNA2 
(TGCTGTTGACAGTGAGCGCTAGCTCAGATCCTTTCCTTAATAGTGAAGCCACAG
ATGTATTAAGGAAAGGATCTGAGCTATTGCCTACTGCCTCGGA); shRNA3 
(TGCTGTTGACAGTGAGCGCCCATTGCTGCTGTTAATGTATTAGTGAAGCCACAG
ATGTAATACATTAACAGCAGCAATGGATGCCTACTGCCTCGGA); and shRNA4 
(TGCTGTTGACAGTGAGCGCGCAATCACTGTGTTGTATATATAGTGAAGCCACAG
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ATGTATATATACAACACAGTGATTGCATGCCTACTGCCTCGGA). For stable 
overexpression of 14-3-3σ in the MCF-10A.14-3-3ζ and MCF-10A.14-3-3ζ.ErbB2 cells, the 
coding sequence was subcloned from pCMV-SPORT6-14-3-3σ (Openbiosystems) into the 
lentiviral expression vector pENTR3C-GFP vector (Invitrogen) to allow for Kanamycin 
antibiotic selection. Finally, it was subcloned into lentiviral vector pLove-14-3-3σ-GFP for 
lentiviral infection. Stable overexpression cell lines were generated as above. 
Cytoplasm and nuclear protein fractionation:  
          Cells were trypsinized, centrifuged at 1000 rpm, and then washed with PBS. The cell 
pellet was resuspended with hypotonic buffer (10 mM HEPES [pH 8.0], 1.5 mM MgCl2, 10 
mM KCl, 1 mM PMSF and protease inhibitor cocktail) and incubation on ice for 15 min. 
Centrifuge at 10,000rpm at 4oC for 5 min to pellet cells. The pellet was then resuspended 
with buffer containing 10 mM HEPES [pH 8.0], 1.5mM MgCl2, 10 mM KCl and 0.05% NP-
40, and incubated on ice for 30 min. Cytoplasmic fractions were separated by 50 strokes of a 
dounce homogenizer (type B pestal). Extracts were centrifuged at 13,000 rpm at 4oC for 10 
min and the supernatant was retained as cytoplasmic fraction. The nuclear pellet was washed 
twice with hypotonic buffer and then pelleted, resuspended with nuclear extract buffer (10 
mM HEPES [pH 8.0], 1.5 mM MgCl2, 400 mM NaCl, 0.1 mM EDTA, and 20% Glycerol), 
followed by incubation on ice for 30 min. A 30-guage syringe was used to break up the 
pellet and release nuclear protein. Extracts were centrifuged at 13,000 rpm at 4oC for 15 
min, and the supernatant was retained as the nuclear fraction. 
Transwell migration assay:  
         231.Vec, 231.σ and 231.ζ cells (1×105 cells/chamber) were resuspended in DMEM and 
added to the top chambers of 24-well transwell plate (Costar, 8-µM pore size). The bottom 
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chamber was filled with 10% FBS containing DMEM (with or without TGF-β) as an 
attractant. After 12 hours of incubation, non-migrated cells on the top side of membrane 
were removed by swiping with Q-tips. The migrated cells on the bottom side of the 
membrane were fixed with 20% methanol and stained with crystal violet for visualization. 
The number of migrating cells in three fields from each well was counted under 20X 
magnifications.    
cDNA Microarray and analysis: 
         Two unbiased platforms were applied to gene profiling of MCF-10A.14-3-3ζ cells 
compared to MCF-10A.Vec and parental cells: one is Human Genome U133 Plus 2.0 Array 
(Affymetrix), which offers comprehensive analysis of genome-wide expression on a single 
array; another one is Whole genome 44K long oligo array (Agilent) in collaboration with the 
cDNA microarray core facility at UT-MDACC. Microarray data were analyzed by using 
Gene Ontology software online (http://bioinfo.vanderbilt.edu/gotm/), and hierarchical 
cluster analysis algorithms and graphical representation of the data were performed by 
aligning our microarray data with the other cDNA microarray data from 19 normal breast 
tissue samples and 43 breast cancer patient samples online using Cluster and Treeview 
software. 
Wound healing assay:  
         Cells were grown to confluence in a 6-well plate, and then scratched using a 200 µL 
sterile pipette tip. Images of wounded monolayers were photographed under an inverted 
microscope at the time of wounding (0 h) and 6 h later. 
RNA extraction, RT-PCR (reverse-transcription–polymerase chain reaction) and 
quantitative real-time RT-PCR:  
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Total RNA from cells was isolated using Trizol reagent (Invitrogen) and protocol 
was followed as per the manufacturer’s instructions. 1 µg of total RNA was reverse 
transcribed to cDNA using iScriptTM cDNA synthesis kit (Biorad) following the 
manufacturer’s instructions. Then, an equivalent volume (1 µl) of cDNA was used as 
template for quantitative real-time PCR with iQTM SYBR Green Supermix (Biorad) and the 
StepOnePlusTM (Applied Biosystems) instrument according to the manufacturer’s 
instruction. The name of the gene quantified and the sequence of the primers are given in the 
following table.  The threshold cycles for specific targets were then normalized to the 
threshold cycles of GAPDH to calculate the relative fold change difference.  
 
Primers: 
gene Primers 
P21 F: 5’-GTCACTGTCTTGTACCCTTGTG-3’ 
R: 5’-CGGCGTTTGGAGTGGTAGAAA-3’ 
P15 F: 5’-CGTGCTGACATCTATGCAAT-3’ 
R: 5’-AGCTGCTCCATTGGCATAC-3’ 
c-myc F: 5’-CCTGGTCAAGAAGCATTTCAA-3’ 
R: 5’-GCCCCAAAGATGAGGAGTATC-3’ 
14-3-3σ F: 5’-TTCTTCTGCGCTACTGCTGCG-3’ 
R: 5’-GGGCAGGTATGGAGAGGAAGA-3’ 
Gli2 F: 5’-AGTTTGTTCTCGGGTGCTCTG-3’ 
R: 5’-ACATCTGTCATCTGAAGCGGC-3’ 
GAPDH 
 
F: 5’-TGGTATCGTGGAAGGACTCATGAC-3’ 
R: 5’-ATGCCAGTGAGCTTCCCGTTCAGC-3’ 
Jagged1 F: 5’- GAGCTATTTGCCGACAAGGC-3’ 
R: 5’- GGAGTTTGCAAGACCCATGC-3’ 
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IL-11 F: 5’-CTCGAGTTTCCCCAGACC-3’ 
R: 5’-GTCAGCTGGGAATTTGTCC-3’ 
PTHrP F: 5’-TTTACGGCGACGATTCTTCC-3’ 
R: 5’-TTCTTCCCAGGTGTCTTGAG-3’ 
 
Osteoblast co-culture assay: 
         MC3T3 cells (3×104 cells/well) were seeded in 6-well plates. After confluence was 
achieved, Luciferase/GFP-labeled (GFP+) 231.scramble, 231.ζKD4, 231.ζKD5, 231.Vec, 
231.σ or 231.ζ cells (1×104 cells/well) were added on top of MC3T3 cell layer in triplicate 
and treated with or without 5ng/ml TGF-β. The co-culture assays were performed in α-MEM 
medium supplemented with 10% FBS and changed every two days. After 6 days the co-
culture was subjected to a luciferase assay to quantify the relative number of tumor cells. 
These values were normalized against luciferase quantification of 6-well plates seeded with 
tumor cells alone. 
Osteoclast co-culture assay: 
         231.scramble, 231.ζKD4, 231.ζKD5, 231.Vec, 231.σ or 231.ζ cells (1×104 cells/well) 
were mixed with murine pre-osteoclast RAW 264.7 cells (3 ×104 cells/well) in medium 
containing 30 ng/ml RANKL, and seeded into 6-well plates together. The co-cultures were 
performed in DMEM medium supplemented with 10% FBS and changed every two days. 
TRAP staining was performed on day six using a leukocyte acid phosphatase kit (Sigma). 
TRAP+-multinucleated cells were scored as mature osteoclasts. The number of nuclei per 
osteoclast was quantified using TRAP-stained images. 
Tumor Xenografts and Bioluminescence Analysis 
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          All procedures involving mice and experimental protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) of University of Texas M.D. 
Anderson Cancer Center. For bone metastasis studies, 2X105 tumor cells were injected into 
the bone of anesthetized female athymic Ncr-nu/nu mice. Development of bone metastases 
was monitored by bioluminescence imaging (BLI). Anesthetized mice were retro-orbitally 
injected with 75mg/kg D-Luciferin. Bioluminescence images were acquired with a Xenogen 
IVIS 200 imaging system. Analysis was performed with live imaging software by measuring 
photon flux in the hindlimbs of mice. Data were normalized to the signal on day 21. Bone 
metastasis-free survival curves represent the time point at which each mouse developed 
bone metastasis by threshold BLI signals in the hindlimbs. 
X-ray analysis and quantification:  
        Osteolysis was assessed by X-ray radiography. Anesthetized mice were exposed to X-
ray radiography at 40 mm for 1 min and directly imaged by Carestream Molecular Imaging 
software using Kodak In-Vivo Multispectral Imaging system. Osteolytic lesions were 
identified on radiographs as demarcated radiolucent lesions in the bone and quantified using 
ImageJ software (National Institutes of Health). 
Histomorphometric analysis and immunohistochemical staining 
       Hindlimb bones were excised from mice at the end point of each experiment, and fixed 
in 10% neutral-buffered formalin, decalcified in 10% EDTA for 2 weeks, and embedded in 
paraffin for hematoxylin and eosin (H&E), tartrate-resistant acid phosphatase (TRAP) (Kos 
et al., 2003), or immunohistochemical staining. Histomorphometric analysis was performed 
on H&E stained bone metastasis samples using the Zeiss Axiovert 200 microscope and 
AxioVision software version 4.6.3 SP1. Immunohistochemical analysis was performed with 
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heat-induced antigen retrieval. Primary antibodies used were anti-14-3-3ζ (Santa Cruz, sc-
1019) and anti-14-3-3σ (abcam, ab14123). Biotinylated secondary antibody was used with 
Vectastain ABC Kit (Vector Laboratories) and DAB detection kit (Zymed) to reveal the 
positively stained cells with nuclei counterstained with hematoxylin. 
Statistical analysis: 
         Statistics were performed using log rank test, chi-square test, or student t-test. p<0.05 
was considered significant.  
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Chapter 3: Results 
14-3-3ζ overexpression inhibits TGF-β cytostatic program in non-transformed human 
mammary epithelial cells through downregulation of p21 
        TGF-β controls a large number of genes through immediate effects on transcriptional 
activation and repression (5, 6, 36). These effects are primarily mediated by the smad2/3 
complex which are directly activated by TGF-β and translocate from the cytoplasm to the 
nucleus (36). In normal epithelial cells, TGF-β induces a cytostatic program involving two 
classes of immediate gene responses (5). One class includes genes encoding the cyclin-
dependent kinase (cdk) inhibitors p15(37) and p21 (38) (39, 40) which inhibit cell cycle 
progression. The other class includes genes that promote cell growth, like c-myc(41) (42, 
43), and Id1/2/3(44) . The two different readouts could be due to the smad2/3 complex 
binding together with different transcriptional partners to either repress (E2F4/5 and p107 or 
ATF3) or activate (p53 or FOXO3a) gene expression. However, in the late phase of tumor 
progression, the major function of TGF-β is to induce EMT through transcriptional 
upregulation of numerous factors, including SNAIL1(45), HMGA2 (46), ZEB1 (47) and 
ZEB2 (SIP1)(48). These factors are crucial for repressing E-cadherin and other tight 
junction molecules. TGF-β and 14-3-3ζ are known to corporately affecting cell proliferation 
and tumorigenesis. However, the critical regulatory mechanism linking 14-3-3ζ to the TGF-
β signaling pathway in breast cancer initiation and progression remains unclear. To address 
this question, we have stably introduced 14-3-3ζ into the non-transformed MCF10A Human 
Mammary Epithelial cells (HMEC) and established the 14-3-3ζ overexpressing stable line 
MCF-10A.14-3-3ζ (Fig.1c).  
 
  
 
Figure 1. 14-3-3ζ overexpression inhibits TGF-β’s cytostatic function in MCF-10A 
cells. a) MCF-10A.Vec or MCF-10A.14-3-3ζ cells were treated with TGF-β (5ng/ml) or 
vehicle. Cells were counted every 24 hours and plotted as percent inhibition relative to 
vehicle control. b)  BrdU incorporation assay in MCF-10A parental cell, MCF-10A.Vec and 
MCF-10A.14-3-3ζ cells treated with TGF-β (5ng/ml) or vehicle. The percentage of cell 
proliferation was calculated after 72 hours treatment and normalized to the group without 
treatment. c)  Western blot analysis of TGF-β signaling pathway in MCF-10A.Vec and 
MCF-10A.14-3-3ζ with or without TGF-β treatment for 2 hours. 
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        Our lab has previously published that 14-3-3ζ stabilizes TGFβRI and promotes the 
TGF-β induced EMT program in MCF-10A.14-3-3ζ cells through SIP1/ZEB2, a repressor of 
E-cadherin (19). Interestingly, I found that 14-3-3ζ in MCF-10A cells not only promotes 
EMT, but also simultaneously blocks the cytostatic program induced by TGF-β making 
10A.14-3-3ζ cells much more resistant to TGF-β induced cell growth inhibition (Fig.1a, b). 
These results have been confirmed in another kind of HMEC system-MCF-12A cells 
(Fig.2a, b). Meanwhile, I found that p21, the key downstream effector responsible for TGF-
β induced cell cycle arrest, is downregulated in 10A.14-3-3ζ cells compared to 10A.Vec 
cells (Fig.3 a, b). Moreover, 14-3-3ζ overexpression also inhibits TGF-β induced p21 gene 
expression (Fig.3 a, b). I examined whether 14-3-3ζ overexpression inhibits TGF-β induced 
p15 gene expression or whether it affects TGF-β’s inhibition of c-myc gene expression. 14-
3-3ζ overexpression inhibits TGF-β induced p15 gene expression as shown in Fig.4a. 
However, p15 may not be the major downstream executor of TGF-β’s cytostatic program in 
MCF-10A cells because these cells have trace levels of p15 protein expressed. In addition, I 
found that 14-3-3ζ overexpression does not change TGF-β’s inhibition of c-myc 
dramatically, although 14-3-3ζ overexpression indeed upregulates endogenous c-myc gene 
expression (Fig.4b). 
 
 
 
 
 
 
 
Figure 2. 14-3-3ζ overexpression inhibits TGF-β’s cytostatic function in MCF-12A 
cells. a)  Western blot analysis of TGF-β signaling pathway in MCF-12A.Vec and MCF-
12A.14-3-3ζ with or without TGF-β treatment for 2 hours. b) MCF-12A.Vec or MCF-
12A.14-3-3ζ cells treated with TGF-β (5ng/ml) or vehicle. Cells were counted every 24 
hours and plotted as percent inhibition relative to vehicle control.  
 
 
 
 
 
 
 
 
  21
 
 
Figure 3. 14-3-3ζ overexpression switches off TGF-β’s cytostatic program through 
inhibiting p21 expression. a)  Western blot analysis of MCF-10A.Vec and MCF-10A.14-3-
3ζ with or without TGF-β treatment for 2 hours. b) RT-PCR analysis of p21 mRNA level in 
MCF-10A.Vec or MCF-10A.14-3-3ζ cells treated with TGF-β (5ng/ml) or vehicle for 2 
hours. Normalized to GAPDH and relative to 10A.14-3-3ζ cells 
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Figure 4. 14-3-3ζ overexpression switches off TGF-β’s cytostatic program, but not 
through p15 or c-myc.   
RT-PCR analysis of p21 mRNA level (Left panel) and c-myc mRNA level (right panel) in 
MCF-10A.Vec or MCF-10A.14-3-3ζ cells treated with TGF-β (5ng/ml) or vehicle for 2 
hours. Normalized to GAPDH and relative to 10A.Vec cells. 
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        To further test if p21 is the final executor for TGF-β induced cell proliferation 
inhibition in MCF-10A cells, I knocked down p21 in MCF-10A cell (Fig.5a) and found that 
MCF-10A.p21shRNA233 and MCF-10A.p21shRNA535 are resistant to the cell 
proliferation inhibition function of TGF-β compared to MCF-10A.scramble cells (Fig.5b). 
Additionally, I found that TGF-β still can induce p21 gene expression partially after p21 
knockdown in MCF-10A cell, which suggests that the upstream regulator of p21 expression 
is still imperturbable (Fig. 6). Taken together, our data indicate that TGF-β induces p21 gene 
expression to inhibit cell proliferation in non-transformed human mammary epithelial cells, 
and 14-3-3ζ overexpression inhibits TGF-β’s cytostatic program in normal epithelial cells 
through downregulation of p21.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5. Knockdown of p21 in MCF-10A cells inhibits TGF-β’s cytostatic function.  
a)  Multiple MCF10A stable clones were established with p21 knockdown. Immunoblot 
analysis of p21 is shown. b) MCF-10A.scramble, MCF-10A.p21shRNA233, and MCF-
10A.p21shRNA535 cells treated with TGF-β (5 ng/ml) or vehicle for 24, 48, 72 hours 
respectively. Cell proliferation was measured by counting cell number with a Levy 
hemocytometer. Data are presented as the mean ± SD of three independent experiments. 
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Figure 6. p21 is the final executor of TGF-β’s cytostatic program in non-transformed 
human mammary epithelial cells.  
Western blot analysis of TGF-β’s cytostatic program in MCF-10A.scramble and MCF-
10A.p21shRNA233 cells treated with TGF-β (5ng/ml) or vehicle for 2 hours.  
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Destabilization of p53 by 14-3-3ζ overexpression suppresses TGF-β induced p21 
expression 
        In mammalian cells, the full transcriptional activation of the CDK inhibitor p21 by 
TGF-β requires a specific co-transcription activator to co-operate with smad complexes. 
However, this signaling cascade is cell-context dependent. The forkhead box (Foxo) family 
of transcription factors especially FOXO3a, has been reported to form complexes with 
smad3/4 to turn on p21 in response to TGF-β in HaCaT cells. This effect can be negatively 
regulated by PI3K-Akt activation because Akt directly phosphorylates FOXO3 and forces 
FOXO3 out of nucleus, thereby preventing it ability to activate p21 gene transcription (38). 
Moreover, 14-3-3 has been shown to be responsible for sequestering FOXO3 in the cytosol 
after Akt phosphorylation (49), so we tested whether 14-3-3ζ overexpression blocks the 
complex formation of FOXO3 and smads. However, we did not find that FOXO3a could 
form a complex with smads in response to TGF-β stimulation in MCF-10A cells as the 
previously shown (Fig. 7), this might suggest that in different cell contexts, TGF-β signaling 
pathway may utilize different co-transcription factors together with smads to turn on p21 
expression.  
 
 
 
 
 
 
 
 
 
Figure 7. Foxo3a does not form a complex with smad4 in response to TGF-β in MCF-
10A cells.  
 MCF-10A.Vec cells were treated with TGF-β (5ng/ml) or vehicle for 2 hours. Total cell 
lysates were collected followed by Immunopreciptation with Foxo3a antibody, and 
immunoblot analysis of smad4 as indicated.  
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        In addition to FOXO3, p53 also has been shown to be required for TGF-β induced p21 
expression (50-52), and 14-3-3ζ overexpression can lead to p53 downregulation through 
activating the PI3K/Akt pathway, which leads to phosphorylation and translocation of the 
MDM2 E3 ligase, resulting in increased p53 degradation (3). Therefore, we examined 
whether p53 can form a complex with smads in MCF-10A cells. In the absence of TGF-β 
stimulation, p53 does not bind to smad2 in MCF-10A.vec cells (Fig. 8). However, in MCF-
10A.14-3-3ζ cells, 14-3-3ζ overexpression downregulates p53 (Fig.2 & Fig.3), and thereby 
downregulates endogenous p21 expression which is important for TGF-β’s cytostatic 
function as indicated previously. After TGF-β treatment, we found that p53 binds to smad2 
in MCF-10A cells (Fig 8), but in 10A.ζ cells, TGF-β cannot induce p21 expression due to 
lack of co-transcription factor p53 (Fig.2 & Fig.3). These data suggests that in human 
mammary epithelial cells, p53 is the major co-transcription factor required for TGF-β 
induced p21 expression, and downregulation of p53 by 14-3-3ζ blocks TGF-β’s cytostatic 
program.  
 
 
 
 
 
 
 
 
 Figure 8.  p53 forms a complex with smad2 in response to TGF-β in MCF-10A cells.   
MCF-10A.Vec treated with TGF-β (5ng/ml) or vehicle for 2 hours. Total cell lysates were 
collected and immunoprecipitated with smad2 antibody followed by immunobloting analysis 
of p53 as indicated.  
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14-3-3σ downregulation by 14-3-3ζ overexpression contributes to destabilization of p53 
in non-transformed HMEC cells  
        Our previous data has shown that p53 downregulation in MCF-10A.14-3-3ζ cells is due 
to activation of the PI3K/Akt pathway by 14-3-3ζ overexpression, which phosphorylates 
MDM2 resulting in proteasomal degradation of p53 (3). However, 14-3-3σ, another 14-3-3 
family member, has been reported to inhibit Akt activation (53) and stabilize p53 in an 
opposite fashion (54). In addition, to obtain an unbiased and comprehensive view of 14-3-
3ζ-mediated molecular alterations, I performed cDNA microarrays in MCF-10A.14-3-3ζ 
cells versus MCF-10A.vec control cells grown under 3D culture conditions. Interestingly, I 
found that 14-3-3σ is downregulated in MCF-10A.14-3-3ζ cells compared to MCF-10A.Vec 
cells (Fig. 9a). These findings were confirmed by RT-PCR and western blot in both MCF-
10A and MCF-12A cells (Fig. 9b, c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 9.  14-3-3ζ overexpression leads to downregulation of 14-3-3σ via 
transcriptional inhibition. 
a) Gene expression profiling on 10A.parental, 10A.vec and 10A.14-3-3ζ cells using cDNA 
microarray.  Heat map depicts top gene alterations in 10A.14-3-3ζ cells versus 10A.Vec 
cells. b) RT-PCR analysis of 14-3-3σ mRNA level in 10A.parental, 10A.Vec, and 10A.14-3-
3ζ cells (left panel). RT-PCR analysis of 14-3-3σ mRNA level in 12A.parental, 12A.Vec 
and 12A.14-3-3ζ cells was also performed (right panel). c) Western blot analysis of 14-3-3σ 
and 14-3-3ζ protein level in MCF-10A sublines and MCF-12A sublines. β-actin was used as 
a loading control. 
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        To test if 14-3-3σ downregulation by 14-3-3ζ overexpression contributes to 
destabilization of p53 in non-transformed HMEC cells, I knocked down 14-3-3σ in 10A 
cells and found that phosphorylation of Akt increased and p53 was downregulated in MCF-
10A.14-3-3σshRNA128 cells compared to MCF-10A.Scramble cells (Fig. 10a). Consistent 
with this, p53 was recovered and Akt activation was inhibited after 14-3-3σ was rescued in 
MCF-10A.14-3-3ζ cells (Fig. 11a). To further investigate if downregulation of 14-3-3σ is 
critical for 14-3-3ζ blocking the TGF-β induced cytostatic program, I treated MCF-10A.14-
3-3σshRNA128 cells with TGF-β and found that 14-3-3σ knockdown renders MCF-10A 
cells resistant to TGF-β-mediated cell growth inhibition (Fig.10b, c), and inhibits TGF-β 
induced p21 expression (Fig. 10a). Additionally, rescuing 14-3-3σ in MCF-10A.14-3-3ζ 
cells renders MCF-10A.14-3-3ζ cells sensitive to TGF-β treatment (Fig.11b), and also 
recovers TGF-β induced p21 gene expression in MCF-10A.14-3-3ζ.14-3-3σ cells (Fig.12). 
Taken together, these data suggest that 14-3-3ζ and 14-3-3σ play an opposite role in 
mediating TGF-β induced p21 gene expression and cell proliferation inhibition. Importantly, 
these data may support the hypothesis that 14-3-3ζ-mediated downregulation of 14-3-3σ 
leads to destabilization of p53 in non-transformed human mammary epithelial cells and 
switches off TGF-β’s tumor suppressor function in the early stage of breast cancer 
development to contribute to the progression of breast cancer.  
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Figure 10.  knockdown of 14-3-3σ inhibits TGF-β’s cytostatic function. 
a) After knockdown of 14-3-3σ in MCF-10A cells, MCF-10A.scramble and MCF-
10A.σsh128 cells treated with TGF-β (5ng/ml) or vehicle for 2 hours followed by Western 
blot analysis of TGF-β’s cytostatic program in 10A.scramble and 10A.σsh128 cells. b) 
MCF-10A.scramble or MCF-10A.σsh128 cells were treated with TGF-β (5ng/ml) or vehicle. 
Cells were counted every 24 hours and plotted as percent inhibition relative to vehicle 
control. c) BrdU incorporation assay on 10A.scramble and 10A.σsh128 cells treated with 
TGF-β (5ng/ml) or vehicle for 72 hours. The percentage of cell proliferation was calculated 
after 72 hours treatment and normalized to the group without treatment. 
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 Figure 11.  14-3-3σ downregulation contributes to PI3K-Akt activation and p53 
destabilization induced by 14-3-3ζ overexpression, thereby contributes to the inhibition 
of TGF-β’s cytostatic program by 14-3-3ζ overexpression. 
a) 14-3-3σ expression was rescued in 10A.14-3-3ζ and 10A.ErbB2.14-3-3ζ cells and western 
blot analysis of p-Akt, T-Akt, 14-3-3σ, 14-3-3ζ in 10A.vec, 10A.14-3-3ζ, 10A.14-3-
3ζ.sigma cells (Left panel) and 10A.ErbB2.14-3-3ζ and 10A.ErbB2.14-3-3ζ.sigma cells 
(right panel) was performed. β-actin was used as a loading control. b) BrdU incorporation 
assay in 10A.vec, 10A.14-3-3ζ, 10A.14-3-3ζ.sigma cells treated with TGF-β (5ng/ml) or 
vehicle for 72 hours.  
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 Figure 12.  Rescue of 14-3-3σ in 10A.14-3-3ζ cells recovers the cytostatic function of 
TGF-β. 
After rescue of 14-3-3σ in MCF-10A.14-3-3ζ cells, the MCF-10A sublines were treated with 
TGF-β (5ng/ml) or vehicle for 2 hours as indicated followed by Western blot analysis of 
TGF-β’s cytostatic program in MCF-10A sublines.  
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14-3-3ζ overexpression downregulates 14-3-3σ in the early stage of breast cancer 
development though sequestering YAP1 transcription factor in the cytosol 
        I have already found 14-3-3σ (SFN) was significantly downregulated in 10A.14-3-3ζ 
cells compared to 10A.vec cells (Fig. 9a), and confirmed cDNA microarray data at both 
mRNA and protein level by performing RT-PCR and western blot (Fig. 9b, c). To test if this 
is a cell specific phenotype or retrovirus effect, I established another 14-3-3ζ overexpressing 
HMEC cell line in MCF-12A cells by transduction with a lentiviral vector containing 14-3-
3ζ gene with an N-terminal HA-tag. Consistent with my previous findings in MCF-10A 
cells, I found a downregulation of 14-3-3σ expression following 14-3-3ζ overexpression 
(Fig. 9b, c). Additionally, I found that 14-3-3σ is upregulated at both the mRNA and protein 
level in 14-3-3ζ-/- Mouse embryonic fibroblast (MEF) cells compare to 14-3-3ζ+/+ and 14-
3-3ζ+/- MEF cells (Fig. 13). Moreover, 14-3-3σ is downregulated by 14-3-3ζ 
overexpression in the mammary gland tissues at lactation day 20 of WAP-HA-14-3-3ζ 
mouse compared to wild type mice (Data not shown). To investigate if this regulation is 
prevalent in breast cancer, I also determined 14-3-3ζ and 14-3-3σ protein level in a panel of 
cell lines including non-transformed HMEC cells and malignant breast cancer cells, and 
found out that 14-3-3ζ is generally highly expressed in breast cancer cells compared to non-
transformed HMEC cells; however, the expression of 14-3-3σ is lost in breast cancer cells 
compared to non-transformed HMEC cells (Fig. 14). These data suggest that downregulation 
of 14-3-3σ by 14-3-3ζ overexpression is a prevalent phenomenon that exists in breast cancer 
cells, and this regulation may contribute to the dynamic balance of 14-3-3 family members 
in breast cancer development and dimorphic function of these two well-known members.  
 
 Figure 13.  14-3-3σ is upregulated in 14-3-3ζ knockout mice. 
a) Western blot analysis of 14-3-3σ protein level in MEF cells from wild type, 14-3-3ζ+/-, 
14-3-3ζ-/- mice. b) RT-PCR analysis of 14-3-3σ protein level in MEF cells from wild type, 
14-3-3ζ+/-, 14-3-3ζ-/- mice. 
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 Figure 14.  14-3-3ζ and 14-3-3σ are inversely correlated in a panel of non-transformed 
HMEC cells and breast cancer cells. 
Western blot analysis of 14-3-3σ and 14-3-3ζ protein level in a panel of non-transformed 
HMEC cells and breast cancer cells.   
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        Since I found that downregulation of 14-3-3σ by 14-3-3ζ overexpression is at the 
mRNA level, I investigated the mechanism by which 14-3-3ζ regulates the mRNA of 14-3-
3σ. The transcription and expression of 14-3-3σ can be regulated in multiple ways. For 
example, P53 can induce 14-3-3σ in response to ionizing radiation and DNA damage (16). 
p53 is dephosphorylated and activated following cellular DNA damage, and it then binds to 
the promoter region of 14-3-3σ, and lead to increased transcription of 14-3-3σ and G2/M 
arrest (16, 55). In basal/progenitor cell, 14-3-3σ expression may be repressed by ΔNp63, a 
dominant negative isoform which can suppress both p53 and TAp63 transactivation (21, 23). 
To test if downregulation of 14-3-3σ in 10A.14-3-3ζ cell is due to increased proteasomal 
degradation of transcitption factor-p53, I rescued p53 in 10A.14-3-3ζ cells by treating 
10A.14-3-3ζ cells with MG132, but I did not find 14-3-3σ was recovered in 10.14-3-3ζ cell 
along the time course (Fig. 15). Although p53 and ΔNp63 have been reported to be the 
major regulator of 14-3-3σ expression in cell lines, no association between 14-3-3σ 
expression and p53 mutations or increased level of ΔNp63 was seen in human tissue, 
suggesting that the constitutive expression of 14-3-3σ may be dependent on factors other 
than p53(32), and p53 probably transactives 14-3-3σ expression only in response to DNA 
damage stimuli. In addition, 14-3-3σ also can be regulated by estrogen-induced zinc finger 
protein (EFP). Through interacting with EFP, 14-3-3σ gets ubiquitinylated and quickly 
degraded by EFP in breast epithelial cells (24). Recently, Gene silencing of 14-3-3σ, mainly 
modulated by CpG methylation in the promoter region, has been reported in several types of 
solid tumor, including prostate, lung, breast, skin cancer, and also in hematologic 
malignancies (25-28, 31). To test this, I determined the promoter methylation level of 14-3-
3σ in 10A.14-3-3ζ cells by performing bisulfite genomic sequencing (Fig. 16a). There was 
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no difference in the methylation level in 10A.14-3-3ζ cells compared to 10A.Vec cells. 
Additionally, 14-3-3σ protein could not be recovered after treating 10A.14-3-3ζ cells with 
DNA methylation inhibitor 5-Aza-2’-deoxycytidine (Fig. 16b). Collectively, these data 
suggest that 14-3-3σ mRNA level downregulation by 14-3-3ζ is neither due to decrease of 
p53 nor due to promoter methylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 15.  14-3-3σ downregulation is independent of p53 regulation in 10A cells. 
10A.vec and 10A.14-3-3ζ cells were treated with 10μM MG132 or DMSO as previously 
described, and cell lysates were collected at 4, 8, or 16 hours followed by western blot 
analysis of p53, p21, 14-3-3σ and 14-3-3ζ protein level. β-actin was used as a loading 
control.  
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 Figure 16.  14-3-3σ downregulation is not due to promoter methylation. 
a) Bisulfite Genomic Sequencing analysis of 14-3-3σ promoter CpG islands in 10A.Vec and 
10A.14-3-3ζ cells. The CpG island is depicted on the top left panel, and each vertical bar 
denotes a single CpG. The transcription start site is indicated as an arrow. Two pairs of 
primers are indicated as red bars which are located both upstream and downstream of the 
transcription start site. Ten single clones are represented for each sample. Black and white 
circles represent methylated and unmethylated CpG, respectively. Each circle represents one 
CpG site. b) 10A.vec and 10A.14-3-3ζ cells were treated with 5-Aza-2’-deoxycytidine at 
concentrations of 0, 2.5, or 5μM, and cell lysates were collected three days later and 
followed by western blot analysis of 14-3-3σ and 14-3-3ζ protein level.   
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        In addition, I found that 14-3-3σ mRNA decrease in MCF-10A.14-3-3ζ cells is not due 
to mRNA stability decrease as shown by 14-3-3σ mRNA decay assay (Fig. 17). To 
investigate the transcription repression mechanism mediated by 14-3-3ζ, I created a series of 
5’ deletion mutation constructs of the 14-3-3σ promoter (Fig. 18a) to find the specific 
promoter region responsible for its transcriptional repression by 14-3-3ζ. Interestingly, I 
found a specific promoter region of 181bp (from -922bp to -741bp) to be the transcription 
factor binding region responsible for transcription activation of 14-3-3σ (not including p53 
binding sites, Fig. 18b). After analysis of this specific promoter region by online software 
(Targetscan and TESS, http://www.cbil.upenn.edu/), I found that there are several 
transcription factor binding sites within this region (Fig. 18a). Therefore, I mutated these 
binding sites individually and found that one of these sites (M2) is responsible for 
transcription activation of 14-3-3σ, which is a binding site for the transcription co-activator 
YAP1 (Fig. 18c). To test if YAP1 is the transcription activator for 14-3-3σ, I knocked down 
YAP1 in 10A cells, and found that 14-3-3σ is downregulated at both the mRNA and protein 
level(Fig. 19a, b). In summary, I have found that YAP1 is a novel transcription activator for 
14-3-3σ in HMEC cells.  
 
 
 
 
 
 
 
 Figure 17.  14-3-3σ downregulation is not due to reduced RNA stability in 10A.14-3-3ζ 
cells. 
10A.vec and 10A.14-3-3ζ cells were treated with the transcription inhibitor Antinomycin D 
at concentration of 5 μg/ml, and total mRNA was collected at 0, 1, 2, and 4 hours. RNA 
decay curve shows the remaining 14-3-3σ mRNA level. The value at time 0 was taken as 
100%. 
 
 
 
 
 
 
 
 
 
 
  46
  
Figure 18.  YAP-1 is the transcription factor for 14-3-3σ in 10A cells. 
a) The top panel shows a schematic representation of the luciferase reporter gene driven by 
sequential deletion of the 14-3-3σ promoter. The bottom panel shows a schematic 
representation of the luciferase reporter gene driven by specific transcription factor binding 
site mutations in the 14-3-3σ promoter (922bp). b) Relative luciferase activity of pGL3-
1221, pGL3-922, and pGL3-741 in MCF-10A.Vec and MCF-10A.14-3-3ζ cells. c) Relative 
luciferase activity of different site mutations of pGL3.14-3-3σ.922 in MCF-10A.Vec cells. 
pRL.TK plasmid was co-transfected and used as a transfection efficiency control. Relative 
luciferase activity was determined 48 hr porst-transfection. Error bars indicate SEM. 
 
 
  47
 Figure 19.  Knockdown of YAP1 leads to downregulation of 14-3-3σ in 10A cells. 
Multiple stable clones expressing YAP1 shRNA were established, and most experiments 
were repeated with different clones to rule out shRNA clonal effects. a) Western blot 
analysis of 3 sublines for the indicated proteins is shown. b) qRT-PCR analysis of two 
representative sublines measuring 14-3-3σ mRNA level. 
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        Previous studies discovered that 14-3-3 can bind to YAP1 and retain it in the 
cytoplasm, and therefore inhibits YAP1 transcription activity (56). Their results combined 
with my data suggest that 14-3-3ζ may bind to YAP1 and block its shuttling from cytoplasm 
to nucleus to transactivate 14-3-3σ. To test this hypothesis, I performed an 
immunoprecipitation assay using anti-HA antibody to pull down 14-3-3ζ and found that 14-
3-3ζ binds to phosphorylated YAP1 (Fig. 20) and sequesters YAP1 outside of the nucleus 
(Fig. 21) in 10A.14-3-3ζ cells. Taken together, our data suggest 14-3-3ζ overexpression 
downregulates 14-3-3σ in HMEC cells through sequestering YAP1 in the cytoplasm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 20.  14-3-3ζ binds to p-YAP-1 in 10A.14-3-3ζ cells. 
10A.14-3-3ζ cell lysates were immunoprecipitated by anti-HA antibody, followed by 
immunoblot analysis of p-YAP1. 
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 Figure 21.  14-3-3ζ overexpression retains YAP-1 in the cytosol of 10A cells. 
MCF-10A.Vec and MCF-10A.14-3-3ζ cells were lysed for cell fractionation followed by 
western blotting. Lamin B and tubulin were used as markers for the nucleus and the 
cytoplasm, respectively. 
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14-3-3ζ overexpression promotes TGF-β induced bone metastatic colonization through 
activating PTHrP expression 
        In our previous study, we found that 14-3-3ζ overexpression is critical for TGF-β 
induced EMT program (19). However, the direct link between 14-3-3ζ overexpression and 
TGF-β induced breast cancer metastasis is still unknown. Bone is one of the metastatic sites 
for breast cancer, and bone metastasis is characterized by debilitating bone fractures, severe 
pain, nerve compression, and hypercalcemia (57). The development and outgrowth of these 
secondary lesions depends on the intricate cellular and molecular interactions between breast 
tumor cells and stromal cells of the bone microenvironment(58). One of the abundant 
cytokines secreted in the bone microenvironment is TGF-β, and it is well known that TGF-β 
plays an important role in breast cancer bone metastasis (59).  
         To test whether 14-3-3ζ overexpression in breast cancer cells is essential for TGF-β 
mediated bone metastasis, I knocked down 14-3-3ζ in MDA-MB-231 cells, which have 
significantly higher 14-3-3ζ expression compared to non-transformed HMEC cells (MCF-
10A) (Fig. 14& 22), and tested their migration ability by performing wound healing assays 
and transwell migration assays, I found that knocking down 14-3-3ζ in MDA231 cells can 
dramatically impair TGF-β (5 μg/ml) induced cancer cell migration (Fig. 23). Additionally, 
14-3-3ζ knockdown also inhibited MDA231 cells invasion ability under TGF-β stimulation 
and also without stimulation (Figure not shown). Since TGF-β is the key player in the 
“vicious cycle” of bone metastasis (60), I sought to determine whether knocking down 14-3-
3ζ in MDA231 cells impairs the crosstalk of tumor cells with the bone microenviroment. A 
panel of MDA231 sublines was co-cultured with osteoblasts (MC3T3) and osteoclasts 
(RAW264.7) cells in vitro under the stimulation of TGF-β or no treatment to investigate the 
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effect of 14-3-3ζ on the TGF-β-mediated vicious cycle. The results showed a 3-fold increase 
in the number of MDA231.14-3-3ζ KD tumor cells compared to scramble control when 
treated with TGF-β after normalization to the counts without coculture (Fig. 24a, b) in the 
co-culture system with MC3T3 osteoblast cells. However, without TGF-β stimulation, there 
is no significant difference between 14-3-3ζ knockdown cells and control cells (Fig. 24a, b). 
Interestingly, I also found that knockdown of 14-3-3ζ in MDA231 cells does not change the 
proliferation of cancer cells in response to TGF-β in the non-coculture system (Fig. 25). This 
suggests that knockdown of 14-3-3ζ itself cannot affect proliferation ability when co-
cultured with osteoblast cells, but rather loss of 14-3-3ζ inhibits TGF-β mediated tumor cell 
growth and interaction with osteoblast cells. In addition, I also tested the role of 14-3-3ζ in 
TGF-β-mediated tumor cell interaction with osteoclast cells by directly coculturing tumor 
cells with pre-osteoclast RAW264.7 cells. Strikingly, co-culture of MDA231.14-3-3ζ KD 
cells showed a dramatic decrease in TRAP+ osteoclasts relative to controls (Fig. 26). 
Collectively, these findings reveal that 14-3-3ζ overexpression in breast cancer cells 
promotes TGF-β-induced cancer cell proliferation in the bone microenvironment and 
activates osteoclast maturation and differentiation, thereby contributing to TGF-β-induced 
osteolytic effect.  
 
 
 
 Figure 22.  Knockdown of 14-3-3ζ in MDA-MB231 cells. 
After 14-3-3ζ knockdown in MDA-MB231 cells, 231.scramble, 231.ζKD4, and 231.ζKD5 
cells were treated with TGF-β or vehicle at concentration of 5 μM, and cell lysate were 
collected at two hours followed by western blot analysis of 14-3-3ζ, p-smad2, and T-
smad2/3 protein level. Phosphorylated-smad2 (p-smad2) indicates activation of the TGF-β 
pathway and T-smad2/3 serves as a loading control. 
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 Figure 23.  Knockdown of 14-3-3ζ in MDA231 cells inhibits cancer cell migration in 
response to TGF-β. 
Wound healing assay of the indicated MDA231 sublines with treatment of TGF-β (5ng/ml) 
or vehicle. Wound closures were photographed at 6 hours after wounding. The scale bar 
represents 200μm.  
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Figure 24.  Knockdown of 14-3-3ζ in MDA231 cells inhibits cancer cell proliferation in 
the co-culture system with MC-3T3 osteoblast cells. 
231.scramble, 231.ζKD4, and 231.ζKD5 cells were co-cultured with MC-3T3 osteoblasts 
cells. In the co-culture system cells were treated with TGF-β at concentration of 5 ng/ml or 
vehicle, a) Representative images of coculture from each experimental group. Scale bar, 200 
μm. b) Quantification of tumor cells from co-cultures with MC3T3 from each experimental 
group. 
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 Figure 25.  Knockdown of 14-3-3ζ in MDA231 cells does not change cancer cell 
proliferation in response to TGF-β. 
Equal numbers of MDA231 sublines were seeded and treated with TGF-β (5 ng/ml) or 
vehicle, and cell proliferation was measured by counting cell number with a Levy 
hemacytometer. Data are presented as the mean ± SD of three independent experiments. 
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 Figure 26.  Knockdown of 14-3-3ζ in MDA231 cells inhibits osteoclasts differentiation 
in the co-culture system with Raw264.7 osteoclast cells. 
231.scramble, 231.ζKD4, and 231.ζKD5 cells were co-cultured with RAW264.7 osteoclast 
cells for 5 days. Representative images of TRAP+ staining of osteoclasts from the coculture 
system. The red arrows indicate mature TRAP+ osteoclast cells. 
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        To directly test whether 14-3-3ζ is functionally important for TGF-β-induced breast 
cancer bone metastasis, I labeled the previously described MDA231 sublines with a GFP-
Luciferase reporter and injected these cells into athymic nude mice via intra-tibial injection. 
The progression of bone metastases was monitored by weekly bioluminescence imaging 
(BLI). Knockdown of 14-3-3ζ significantly extended survival and delayed the onset of bone 
metastasis in mice (Fig. 27). I also confirmed the difference in bone tumor burden by BLI 
measurement, histomorphometric H&E staining, X-ray analysis and IHC staining specific to 
14-3-3ζ and 14-3-3σ (Fig. 28). BLI analysis showed that 231 control cells generate bone 
metastatic colonies by 5 weeks after injection, and almost 90% of injected mice have bone 
lesions before 7 weeks (Fig. 27). However, only 37.5% of mice injected with 14-3-3ζ 
knockdown cells generate bone metastatic colonies by the endpoint of the experiment (10 
weeks, Fig. 27). Although I found several mice with bone metastasis in the 14-3-3ζ KD 
group, we found this is due to incomplete knockdown of 14-3-3ζ in those lesions as 
determined by H&E staining and IHC staining for 14-3-3ζ (data not shown). These could be 
explained by a possible mechanism that 14-3-3ζ KD cells are heterogeneous, and only those 
cells with 14-3-3ζ expression and response to TGF-β signaling can be selected out by bone 
microenvironment from the whole population and thrive.  I also collected bone lesions from 
those mice and stained with Tartrate-resistant acid phosphatase-positive (TRAP+) marker to 
test whether bone osteolysis is activated in the bone microenviroment. Consistent with our 
hypothesis, histological analysis demonstrated a significant decrease in the number of 
TRAP+ osteoclasts along the bone-tumor interface of bone lesions generated by 14-3-3ζ KD 
cells compared to control cells(data not shown). 
 Figure 27.  Knockdown of 14-3-3ζ in MDA231 cells inhibits cancer cell metastatic 
colonization in bone microenvironment. 
Kaplan-Meier survival curve of mice (n=10) injected intratibially with 231.scramble or 
231.14-3-3ζKD4 cells. 
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 Figure 28.  Knockdown of 14-3-3ζ in MDA231 cells inhibits cancer cell metastatic 
colonization in the bone microenvironment. 
BLI, X-ray, and histological (H&E and IHC) images of bone lesions from two representative 
mice in each experimental group on day 49. Black arrows indicate osteolytic bone lesions in 
the X-ray images and tumor burden in the histological images. Immunohistochemical 
representative images for 14-3-3ζ and 14-3-3σ expression are also shown. 
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        TGF-β downstream targets, including PTHrP, IL-11, Jagged-1 and CTGF, have been 
shown to modulate the invasive and metastatic behavior of MDA231 cells, as well as 
survival in the bone microenvironment (4, 61-63). Our next step was to identify the 
downstream targets of the TGF-β signaling pathway which are significantly affected by 14-
3-3ζ overexpression. After TGF-β treatment in MDA231 sublines for 2 hours, I found that 
knockdown of 14-3-3ζ in 231 cells can inhibit TGF-β-induced PTHrP, Jagged-1 and IL-11 
transcription. In particular, PTHrP gene expression was dramatically inhibited nearly 3 fold 
(Fig. 29 & Fig. 30). All of these data suggest that 14-3-3ζ-mediated PTHrP expression in 
breast cancer cells is critical for TGF-β induced bone metastatic colonization. 
 
 
 
 
 
 Figure 29.  Knockdown of 14-3-3ζ inhibits TGF-β-induced PTHrP gene expression in 
MDA231 cells. 
qRT-PCR analysis of PTHrP mRNA expression in MDA231 cell line and its derivative 
sublines follwing treatment of TGF-β (5 ng/ml) or vehicle control. 
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 Figure 30.  Knockdown of 14-3-3ζ inhibits TGF-β -induced Jagged1 gene expression in 
MDA231 cells. 
qRT-PCR analysis of Jagged1 mRNA expression in MDA231 cells and its derivative 
sublines following treatment of TGF-β (5 ng/ml) or vehicle control. 
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Gli2/smad2 complex is required for TGF-β induced PTHrP expression 
        TGF-β induces PTHrP expression not only through the classical smad2/3/4 signaling 
pathway, but also through non-canonical signaling cascades such as p38 MAPK (64). There 
are several reported transcription factors which are responsible for PTHrP gene expression, 
including Ets1 (65). Overexpression of Gli2 occurs in a variety of cancers and promotes 
cancer progression via regulation of cell cycle progression and apoptosis(66).  A recent 
study showed that Gli2, which is the most transcriptionally active form of the Gli family, is 
directly involved in melanoma invasion and metastasis (67). Moreover, TGF-β can induce 
Gli2 and Gli1 expression through transcriptional activation in breast cancer cell lines (68, 
69). Additionally, TGF-β promotes Gli2-induced expression of PTHrP independent of 
canonical Hedgehog signaling and contributes to breast cancer bone metastasis (70). Runx2 
also contributes to TGF-β-mediated tumor growth and osteolysis and colocalizes with Gli2 
to further activate PTHrP (71). These data suggest that the TGF-β/smads/Gli2 signaling axis 
is very important for cancer progression and metastasis (72). However, the mechanism by 
which Gli2 contributes to TGF-β induced PTHrP expression and the relationship between 
Gli2 and Smads remains elusive.  
        To address a potential relationship between these two components in the TGF-β- 
induced bone metastases program, I treated 231 cells with TGF-β for 2 hours and performed 
an immunoprecipitation assay using smad2 antibody. Interestingly, I found that Gli2 
immediately binds to p-smad2 in response to TGF-β (Fig. 31). However, when 14-3-3ζ was 
knocked down in MDA231 cells, p-smad2 no longer bound to Gli2 (Fig. 32).  Collectively, 
these data suggest that Gli2 binds to smad2 in response to TGF-β signaling and aids smad 
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complex recognition and binding to the PTHrP promoter. This Gli2/smad complex is 
important for TGF-β-induced PTHrP gene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 31.  Smad2 binds to Gli2 in MDA231 cells in response to TGF-β treatment. 
Interaction between Smad2 and Gli2 in MDA231 cells shown by IP-western analysis after 
treatment with TGF-β (5 ng/ml).  
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 Figure 32.  Knockdown of 14-3-3ζ inhibits Smad2 binding to Gli2 in MDA231 cells in 
response to TGF-β treatment. 
Immunoprecipitation of endogenous Gli2 and p-smad2 in 231 and 231.ζKD5 cells upon 
treatment with TGF-β (5 ng/ml) or vehicle.   
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Gli2 stabilization by 14-3-3ζ is critical for TGF-β induced PTHrP expression 
        There are several mechanisms regulating the activity of Gli transcription factors, 
including nuclear-cytoplasmic shuttling (73, 74), and ubiquitination and protein degradation 
(75-79). In 231.14-3-3ζKD cells, I found that Gli2 protein level did not increase after TGF-β 
treatment for 2 hours compared to 231.scramble cells (Fig. 33), while there was no 
difference in mRNA level between 231.scramble cells and 231.14-3-3ζKD cells (Fig. 34). 
Additionally, a recent report showed that the mRNA level of Gli2 reaches a peak at 48hr 
after TGF-β treatment, but protein level increases within 2 hours of TGF-β treatment (69). 
These findings together with our data suggest that TGF-β may also stabilize Gli2 protein in 
addition to increasing its gene expression. Thus, we hypothesize that 14-3-3ζ may regulate 
Gli2 at the protein level in response to TGF-β.  
 
 
 
 
 
 
 
 
 
 Figure 33.  Knockdown of 14-3-3ζ downregulates Gli2 protein level in MDA231 cells in 
response to TGF-β treatment. 
Western blot analysis showing Gli2 and 14-3-3ζ protein levels in the indicated cell lines 
with treatment of TGF-β (5ng/ml) or vehicle control. 
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 Figure 34.  Knockdown of 14-3-3ζ does not change Gli2 mRNA level in MDA231 cells 
in response to TGF-β treatment. 
qRT-PCR analysis of mRNA expression of Gli2 in MDA231 cell line and its derivative 
sublines upon treatment with TGF-β (5 ng/ml) or vehicle. 
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 Figure 35. Schematic diagram depicting 14-3-3ζ-mediated switch of TGF-β function. 
See text for details. 
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Chapter 4: Discussion 
        In this study, I have found that overexpression of 14-3-3ζ inhibits the cytostatic 
program of TGF-β through destabilizing p53 in non-transformed human mammary epithelial 
cells. Mechanistically, I found that 14-3-3ζ overexpression leads to 14-3-3σ downregulation, 
thereby activating the PI3K/Akt signaling pathway, which degrades p53 and further inhibits 
TGF-β induced p21 expression and cell cytostatic function. In addition, I also found that 
overexpression of 14-3-3ζ promotes TGF-β-induced breast cancer bone metastatic 
colonization through stabilizing Gli2, which is an important co-transcriptional factor for p-
smad2 to activate PTHrP expression and bone osteolytic effect. Taken together, we reveal a 
novel mechanism by which 14-3-3ζ dictates the tumor suppressor or metastasis promoter 
activities of the TGF-β signaling pathway through switching p-smad2’s binding partner from 
p53 to Gli2 (Fig. 35). Our results not only provide a better understanding of the important 
role of 14-3-3ζ in early stage breast cancer development, but also deeply impact our 
knowledge of signaling mechanisms underlying the complex roles of TGF-β in cancer, 
which provides us with a more accurate strategy to determine when and how anti-TGF-β 
targeted therapy might be effective.  
TGF-β’s functional switch 
        In normal epithelial cells, TGF-β induces cytostatic genes, including p15(37) and p21 
(38) (39, 40). It also inhibits another category of genes that promote cell growth, including 
c-myc(41) (42, 43). Our study shows that p21 is the major downstream effector of TGF-β’s 
cytostatic program in MCF-10A cells. However, we cannot exclude other downstream genes 
that may also contribute to this program. As indicated in our figure 5, p21 knockdown in 
MCF-10A cells did not make them fully resistant to TGF-β’s cytostatic effect. Additionally, 
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I also found that 14-3-3ζ overexpression inhibits TGF-β induced p15 expression, but MCF-
10A cells have only trace levels of p15 protein which could not contribute to TGF-β’s 
cytostatic program dramatically. 
        It has been well characterized that TGF-β inhibits cell proliferation in normal epithelial 
cells, but promotes cancer cell metastasis. However, the molecular mechanism by which 
TGF-β switches its role remained elusive. There were several studies that attempted to 
address this question, for example, TMEPAI knockdown attenuated TGF-β induced growth 
and motility in breast cancer cells (80), another report demonstrated that epigenetic 
downregulation of DAB2 blocked TGF-β-mediated inhibition of cell proliferation and 
migration in human squamous cells carcinoma (81). However, these studies do not exactly 
provide evidence to show how TGF-β lost its tumor suppressor function in normal epithelial 
cells, as the majority of the data were obtained from cancer cell lines such as MDA231 cells, 
in which TGF-β already executes a tumor promoter function. Additionally, these studies 
focused primarily on cell proliferation and tumor growth, which is only one of TGF-β’s 
functions, but did not address the metastasis-promoting ability of TGF-β. In our study, we 
found direct evidence that overexpression of 14-3-3ζ inhibits TGF-β’s cell cytostatic 
program in non-transformed human mammary epithelial cells, while overexpression of 14-3-
3ζ promotes TGF-β induced breast cancer bone metastatic colonization. In addition, we 
reveal a novel mechanism by which 14-3-3ζ dictates the tumor suppressor or metastases 
promoter activities of the TGF-β signaling pathway through switching p-smad2’s binding 
partner from p53 to Gli2.  
        Since TGF-β plays an important role in cancer development and a variety of other 
diseases, a lot of effort has been placed to develop cancer therapeutics to target TGF-β 
  75
signaling in both the tumor and its microenvironment. Currently, several kinds of TGF-β 
signaling antagonists have been developed and applied to clinical practice, the most 
advanced drug are large molecules, including monoclonal antibodies and antisense 
oligonucleotides. In addition, there are also several orally bioavailable small molecule 
kinase inhibitors developed to target this signaling pathway(82). However, as tumors evolve, 
TGF-β switches its role from being a tumor suppressor to a tumor promoter, and the 
complex nature and dual roles of TGF-β in cancer has impeded the development of effective 
therapies that target only the tumor-promoting activities of TGF-β. Understanding the 
molecular mechanism by which TGF-β switches its role will benefit the development of 
promising agents and strategies. Previously, we have found that 14-3-3ζ overexpression 
occurs in the early stage breast cancer development (ADH)(3) and is overexpressed in more 
that 40% of breast cancer patients which highly correlates with disease recurrence(18). In 
this study, we found that 14-3-3ζ overexpression in early stage breast cancer development 
serves as a novel molecular switch that turning TGF-β from tumor suppressor to tumor 
promoter. This may suggest that the expression level of 14-3-3ζ could serve as a novel 
molecular biomarker that can aid in the selection of appropriate patients who will benefit 
from TGF-β antagonists(7), and it may help determining when and how anti-TGF-β targeted 
therapy might be feasible(6).  
p53’s convergence with the TGF-β signaling pathway 
        Although the signal transduction cascade of TGF-β is quite simple compared to other 
receptor-mediated signal cascades, involving only a few types of smad proteins, the cellular 
responses to TGF-β are complicated and highly dependent on the cell context. This 
versatility could be explained by the physical interactions between smads and a remarkable 
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diversity of DNA sequence-binding transcription factors. To date, those binding partners in 
mammalian cells include bHLH family, Forkhead family, Zinc finger protein family, and 
p53 (83). For example, in neuroepithelial and glioblastoma cells, TGF-β induces smad3/4 to 
form a complex with Foxo3a (38). Sp1 also has been reported to bind with smads to 
transactivate p15 and p21 gene expression in hepatic cells (39, 40). However, our data 
combined with other reports (35, 50, 52, 84) show this complex does not exist in human 
mammary epithelial cells, indicating the TGF-β signaling program is highly cell context-
dependent. In our study, we found that p53 collaborates with smad2/3/4 to transactivate p21 
gene expression in response to TGF-β in MCF-10A cells. Interestingly, it is reported that 
TGF-β induces p21 through a p53-independent mechanism in the HaCaT cell line, which 
contains two mutant alleles of p53 which are unable to activate transcription of p21 (85). 
Taken together, all of these data suggest that TGF-β’s signaling program is highly cell 
context-dependent. 
        In our study, we found overexpression of 14-3-3ζ inhibits the cytostatic program  of 
TGF-β through destabilization of p53 in MCF-10A cells. In late stage of breast cancer 
development, p53 is usually found to be lost or mutated, especially mutant p53 is found in 
almost 50% of breast cancers (86). 14-3-3ζ overexpression has been found in more than 
40% of advanced breast cancers (18) and starts at the early stage of breast cancer 
development-Atypical Ductal Hyperplasia , which is also the transition phase of TGF-β’s 
function (3, 6). This may suggest that 14-3-3ζ overexpression could be one of the 
mechanisms leads to downregulation of p53, thereby contributes to inhibition of TGF-β’s 
cytostatic function in the early transition phase of breast cancer development. In addition, 
p53 mutation also could contribute to TGF-β’s function switch. As shown in previous study, 
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there is a R280K mutation in p53 in MDA231 cells, and this mutant p53 still can form a 
complex with smads, but empowers TGF-β induced metastasis (35).  
14-3-3ζ and 14-3-3σ 
        In our study, we found a novel mechanism by which 14-3-3ζ overexpression 
downregulates 14-3-3σ through transcriptional repression. It is interesting that these two 
proteins belong to the same family, yet the functions of these two members have been well 
characterized to be opposite. This biological specificity of 14-3-3σ could be explained by the 
structure difference between 14-3-3σ and the rest of 14-3-3 family members (87, 88). The 
structure suggests a second ligand binding site (involving residues Met-202, Asp-204, and 
His-206) involved in 14-3-3σ unique ligand discrimination (87). In addition, most of 14-3-3 
family members except 14-3-3σ form homodimers or mixed heterodimers among different 
isoforms, and they shared the similar ligand binding and function.  In contrast, 14-3-3σ only 
forms homodimers. The structural study also reveals a stabilizing ring-ring and salt bridge 
interactions involving Lys-9 and Glu-83 unique to the 14-3-3σ, and rationalizes that 14-3-3σ 
preferentially form homodimer and has destabilized electrostatic interactions with the other 
members to form heterodimers (87). 
        Among the 14-3-3 family, 14-3-3 σ is well recognized as a tumor suppressor gene, and 
is lost in multiple types of cancer (89). Based on our previous findings, 14-3-3ζ 
overepressed in more than 40% of advanced breast cancer (18)and 14-3-3ζ overexpression 
defines high risk for breast cancer recurrence and promotes cancer cells survival. Moreover, 
14-3-3ζ plays an opposite role with 14-3-3σ in many signaling pathway, including PI3K-Akt 
pathway, p53 stabilization, glycolysis and metabolism, polarity and invasion. However, the 
mechanism by which the balance between 14-3-3ζ and 14-3-3σ was broken in mammalian 
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cell is still unclear. Here, we report that a novel mechanism that 14-3-3ζ overexpression 
transcriptional repress 14-3-3σ gene expression through sequestering YAP1 transcription 
factor outside of the nucleus. It would suggest a critical role of YAP1 in maintaining the 
homeostasis of 14-3-3 family in mammalian cell. When the cells harvest gene amplification 
of 14-3-3ζ(18), it will disrupt the balance and lead to downregulation of 14-3-3σ, and tissue 
malfunction and human disease. 
The complicate role of YAP1 in Cancer 
        The Hippo pathway plays an important role in controlling organ size, tissue 
regeneration, stem cell renew and tumorigenesis (90).  The recent findings show that Hippo 
pathway can be regulated by cell polarity, cell adhesion and cell junction proteins, and 
activation of Hippo pathway leads to phosphorylation and inhibition of transcription co-
activators, such as YAP, TAZ, and Yki(91).  In mammalian cell, YAP phosphorylated by 
Lats1/2 at Ser127 site and binds to 14-3-3 leads to subsequent cytoplasmic sequestration and 
inactivation (91).  However, there is an argument of YAP’s role in cancer development. 
Initially, YAP was defined as a tumor suppressor supported by the evidence of working 
together with p73, PML to induce apoptosis in response to DNA damage (92-95). The new 
concept of YAP1 as an oncogene emerge recently as supported by amplification in human 
HCC(96) and transformation ability of YAP in MCF-10A cells(97). The different role of 
YAP in cancer development might be cell context-specific and binding partners dependent. 
As a transcriptional co-activator, YAP1 functions when it is bound to different transcription 
factors. YAP functions as oncogene when it binds to TEAD family transcription factors in 
regulation of CTGF gene expression which promotes cell proliferation (98). In contrast, it 
functions as a tumor suppressor when YAP binding to p73 or p53BP2, which is then 
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inhibited by Akt phosphorylation (56). In our study, I found that 14-3-3ζ overexpression 
downregulates 14-3-3σ through sequestering YAP1 in the cytosol, which suggests that 
YAP1 transactivates 14-3-3σ when located in the nucleus. However, the transcription factor 
which YAP binds to and collaborates with to activate 14-3-3σ gene expression is still 
unknown. In our study, I found that YAP protein level was not altered by 14-3-3ζ 
overexpression, but subcellular localization was changed. On the other hand, majority of 
data suggest YAP1 serves as an oncogene in nucleus, but this does not exclude the 
possibility that YAP1 also function as an oncogene in the cytosol, which is primarily 
retained by 14-3-3 binding. In the study that shown the transformation ability of YAP in 
MCF-10A cells, the exactly localization of YAP that executes the oncogene function is not 
clearly stated (97).  
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Chapter 5: Future studies 
        In our study, we found that p53 binds to smad2/3/4 together in response to TGF-β in 
MCF-10A cells. However, it has been reported that TGF-β induces p21 through a p53-
independent mechanism in HaCaT cell line which contains two mutant alleles of p53, which 
are unable to activate transcription of p21(85). These data would suggest that the cellular 
responses to TGF-β are complicate and highly cell context dependent. To determine if p53 is 
critical for TGF-β induced p21 gene expression in human mammary epithelial cells, I will 
knockdown p53 in MCF-10A cells to see if it impairs TGF-β induced p21 gene expression. 
In addition, it is also necessary to determine if mutant p53 binds to smads in MDA231 cells 
and identify the downstream signaling cascade in late stage of breast cancer development. 
These data will further indicate the critical role of p53 in TGF-β’s cytostatic program and 
support our hypothesis that 14-3-3ζ overexpression switches off TGF-β’s cytostatic program 
through 14-3-3σ downregulation and destabilization of p53. 
        TGF-β can induce Gli2 and Gli1 expression through transcriptional activation in breast 
cancer cell lines (68, 69), and it promotes Gli2-induced expression of PTHrP and contributes 
to breast cancer bone metastasis (70). These data suggest that the TGF-β/smads/GLi2 
signaling axis is very import for cancer progression and metastasis (72). However, the 
mechanism by which Gli2 contributes to TGF-β induced PTHrP expression and the 
convergence effect between Gli2 and Smads remains elusive. It is the first time shown that 
Gli2 binds to smad2 in response to TGF-β in breast cancer cells as indicated in our data. To 
further determine the important role of Gli2 as a co-transcription factor to smads and 
contribution to TGF-β’s metastatic program, it is necessary to knockdown Gli2 in MDA231 
cells to test if it can impair TGF-β induced PTHrP gene expression. In addition, to determine 
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if this smad2/Gli2 complex is critical for PTHrP gene transcription in response to TGF-β 
and whether the complex could be disrupted by 14-3-3ζ knockdown in MDA231 cells, I will 
perform a ChIP assay on the promoter region of PTHrP using specific antibodies 
recognizing Gli2 or smad2 under TGF-β stimulation. 
        In 231.14-3-3ζKD cells, I found that Gli2 protein level was dramatically decreased 
compared to 231.scramble cells after TGF-β treatment for 2 hours but there are no difference 
on mRNA level between 231.scramble cells and 231.14-3-3ζKD cells. These data suggest 
that 14-3-3ζ may regulate Gli2 protein stability in response to TGF-β. As previous study 
shown that Gli2 is targeted for ubiquitination and degradation by β-TrCP Ubiquitin 
Ligase(99). First, I will test if Gli2 has increased ubiquitination in MDA231.14-3-3ζKD 
cells compared to MDA231 control cells. Next, I will investigate the mechanism by which 
14-3-3ζ overexpression prevents Gli2 to be targeted for ubiquitination and degradation by β-
TrCP Ubiquitin Ligase. 
        14-3-3ζ has been knockdown in MDA231 cells to test if lost of 14-3-3ζ can impair 
TGF-β induced breast cancer cells bone metastasis. To further confirm that 14-3-3ζ 
overexpression promotes TGF-β induced breast cancer cells bone metastasis, I will also 
overexpress 14-3-3ζ in McNeuA cells which is derived from MMTV-Neu mice and has 
equal amount of 14-3-3ζ expression as MCF-10A cells, and challenge these GFP-Luciferase 
labeled McNeuA control cells and McNeuA.14-3-3ζ cells to in vivo bone metastatic 
colonization through intra-tibial injection test if 14-3-3ζ overexpression can promote TGF-β 
mediated McNeuA cells bone metastasis. In addition, I will also treat the mice injected with 
McNeuA.14-3-3ζ cells with TGF-βR inhibitor (LY2109761, Eli Lilly) to test if the increased 
bone metastasis is due to upregulated TGF-β signaling mediated by 14-3-3ζ overexpression. 
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This data would be expected to strengthen our hypothesis that 14-3-3ζ overexpression 
switches on TGF-β induced breast cancer cells bone metastasis program.  
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